Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse
- 30 September 2019
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 78 (12), 1669-1676
- https://doi.org/10.1136/annrheumdis-2019-215571
Abstract
Objectives Maintenance of remission has become central in the management of systemic lupus erythematosus (SLE). The importance of interferon-alpha (IFN-α) in the pathogenesis of SLE notwithstanding, its expression in remission has been poorly studied as yet. To study its expression in remission and its prognostic value in the prediction of a disease relapse, serum IFN-α levels were determined using an ultrasensitive single-molecule array digital immunoassay which enables the measurement of cytokines at physiological concentrations. Methods A total of 254 SLE patients in remission, according to the Definition of Remission in SLE classification, were included in the study. Serum IFN-α concentrations were determined at baseline and patients were followed up for 1 year. Lupus flares were defined according to the Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index Flare Index, whereas the Kaplan-Meier analysis and Cox regression analysis were used to estimate the time to relapse and to identify baseline factors associated with time to relapse, respectively. Results Of all patients in remission, 26% displayed abnormally high IFN-α serum levels that were associated with the presence of antibodies specific for ribonucleoprotein (RNP), double stranded (ds)DNA and Ro/SSA60, as well as young age. Importantly, elevated-baseline IFN-α serum levels and remission duration were associated in an independent fashion, with shorter time to relapse, while low serum levels of complement component 3 and anti-dsDNA Abs were not. Conclusion Direct serum IFN-α assessment with highly sensitive digital immunoassay permits clinicians to identify a subgroup of SLE patients, clinically in remission, but at higher risk of relapse.Keywords
Funding Information
- the French Arthritis Foundation
- The Fondation pour la Recherche Médicale
- the Société Nationale Française de Médecine Interne
This publication has 70 references indexed in Scilit:
- Predictive biological markers of systemic lupus erythematosus flares: a systematic literature reviewArthritis Research & Therapy, 2017
- Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016Annals Of The Rheumatic Diseases, 2017
- A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)Annals Of The Rheumatic Diseases, 2016
- Prolonged remission in Caucasian patients with SLE: prevalence and outcomesAnnals Of The Rheumatic Diseases, 2015
- Systemic lupus erythematosusThe Lancet, 2014
- Treat-to-target in systemic lupus erythematosus: recommendations from an international task forceAnnals Of The Rheumatic Diseases, 2014
- Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and OutcomeThe Journal of Rheumatology, 2010
- Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosusLupus, 2010
- Mortality in systemic lupus erythematosusArthritis & Rheumatism, 2006
- TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITYAnnual Review of Immunology, 2005